Reduction of transforming growth factor-β type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma

International Journal of Cancer

Volumn 127, Issue 7, 2010, Pages 1517-1525

  Fukasawa, Hirotaka ^a   Yamamoto, Tatsuo ^a,b   Fujigaki, Yoshihide ^a   Misaki, Taro ^a   Ohashi, Naro ^a   Takayama, Tatsuya ^a   Suzuki, Sayuri ^a   Mugiya, Soichi ^a   Oda, Toshiaki ^a   Uchida, Chiharu ^a   Kitagawa, Kyoko ^a   Hattori, Takayuki ^a   Hayashi, Hidetoshi ^c   Ozono, Seiichiro ^a   Kitagawa, Masatoshi ^a   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Renal cell carcinoma (RCC); Smad ubiquitination regulatory factor 2 (Smurf2); TGF type II receptor (T R II); Transforming growth factor (TGF ); Ubiquitination

Indexed keywords

PROTEASOME; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; SMAD ANCHOR FOR RECEPTOR ACTIVATION; SMAD UBIQUITINATION REGULATORY FACTOR 2; SMAD2 PROTEIN; SMAD4 PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; RNA; SMAD4 PROTEIN, HUMAN; SMURF2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; ATTENUATION; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRADATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY CELL; KIDNEY PARENCHYMA; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; UBIQUITINATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 77956566522     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25164     Document Type: Article

References (31)

1. Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
2. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000;14:627-44.
3. Wrana JL. Regulation of Smad activity. Cell 2000;100:189-92.
4. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
5. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3. (Pubitemid 3021510)
6. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, Utsunomiya J, Kuroki T, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999;18:3098-103.
7. Miyajima A, Asano T, Seta K, Kakoi N, Hayakawa M. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology 2003;61:1072-7.
8. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood CG. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 2003;22:8053-62. (Pubitemid 37175870)
9. Engel JD, Kundu SD, Yang T, Lang S, Goodwin S, Janulis L, Cho JS, Chang J, Kim SJ, Lee C. Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells. Urology 1999;54:164-70.
10. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
11. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000;22:442-51. (Pubitemid 30308270)
12. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000;6:1365-75.
13. Sobin LH, Wittekind C. Union Internationale Contre le Cancer. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002.
14. Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, Uchida C, Aoki M, Hosono M, Kitagawa M, Hishida A. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004;65:63-74.
15. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-14.
16. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, Hishida A. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 2004;101:8687-92.
17. Togawa A, Yamamoto T, Suzuki H, Fukasawa H, Ohashi N, Fujigaki Y, Kitagawa K, Hattori T, Kitagawa M, Hishida A. Ubiquitin-dependent degradation of Smad2 is increased in the glomeruli of rats with anti-thymocyte serum nephritis. Am J Pathol 2003;163:1645-52.
18. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007;177:430-6. (Pubitemid 46054036)
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
20. Curti BD. Renal cell carcinoma. J Am Med Assoc 2004;292:97-100.
21. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004;22:3720-5.
22. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.
23. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29. (Pubitemid 32952643)
24. Moren A, Itoh S, Moustakas A, Dijke P, Heldin CH. Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. Oncogene 2000;19:4396-404.
25. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235-43.
26. Moren A, Hellman U, Inada Y, Imamura T, Heldin CH, Moustakas A. Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem 2003;278:33571-82.
27. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001;98:974-9.
28. Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002;62:7162-5.
29. Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-5S
30. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol 2004;57:773-5.
31. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;276:12477-80. (Pubitemid 33649290)